MannKind (NASDAQ:MNKD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.03, Zacks reports. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. The business had revenue of $76.78 million during the quarter, compared to analyst estimates of $74.99 million.
MannKind Stock Performance
NASDAQ MNKD traded up $0.11 during trading on Friday, hitting $5.34. The stock had a trading volume of 2,987,576 shares, compared to its average volume of 1,998,728. The company has a market capitalization of $1.47 billion, a PE ratio of 76.29 and a beta of 1.28. The company's 50-day moving average price is $5.98 and its two-hundred day moving average price is $6.29. MannKind has a 12 month low of $3.97 and a 12 month high of $7.63.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on MNKD shares. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of MannKind in a research report on Thursday. Wells Fargo & Company started coverage on MannKind in a research report on Friday, December 20th. They issued an "overweight" rating and a $9.00 price objective for the company. Royal Bank of Canada upgraded MannKind from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $7.00 to $10.00 in a research report on Thursday, December 19th. Finally, StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $9.21.
View Our Latest Stock Report on MannKind
MannKind Company Profile
(
Get Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Read More
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
